1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Characteristics of study cohort at baseline^{^a}
Standard Treatment Group (n = 180) Intensive Treatment Group (n = 226)
Follow-up period (median) (yr) 3.86 3.82
Age (yr) 67.5 (SD, 8.4) 68.4 (SD, 8.4)
Female sex (No.) (%) 60 (33.3%) 89 (39.4%)
Race (No.) (%) 
 White 117 (65.0%) 156 (69.0%)
 Black 51 (28.3%) 59 (26.1%)
 Hispanic 9 (5.0%) 7 (3.1%)
 Other 3 (1.7%) 4 (1.8%)
SBP (mm Hg) 139.6 (SD, 18.4) 136.2 (SD, 18.2)
DBP (mm Hg) 82.2 (SD, 13.2) 80.2 (SD, 11.2)
eGFR (mL/min/1.73 m²) 69.1 (SD, 21.3) 65.2 (SD, 19.0)
Serum creatinine level (mg/dL) 1.1 (SD, 0.4) 1.1 (SD, 0.4)
Chronic kidney disease (eGFR <60 mL/min/1.73 m²) (No.) (%) 61 (33.9) 88 (38.9)
Framingham 10-year cardiovascular disease risk score (%) 24.3 (SD, 12.4) 23.5 (SD, 12.6)
TBV (cm³) 1150.9 (SD, 117.0) 1139.3 (SD, 117.3)
rTBV/ICV) 0.82 (SD, 0.04) 0.82 (SD, 0.04)
White matter lesion volume (median) (IQR) (cm³) 1.6 (0.9–3.8) 1.4 (0.6–3.6)
Note:—DBP indicates diastolic blood pressure; IQR, interquartile range; eGFR, estimated glomerular rate; ICV, intracranial volume.
↵a All values provided as means unless otherwise specified.